|Bid||0.00 x 900|
|Ask||0.00 x 1200|
|Day's range||163.89 - 166.34|
|52-week range||155.72 - 186.69|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||24.46|
|Earnings date||18 Apr 2023|
|Forward dividend & yield||4.52 (2.74%)|
|Ex-dividend date||17 Feb 2023|
|1y target est||183.63|
In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adria Cimino and Keith Speights talk about why these two stocks actually make great buys right now. Adria Cimino (Johnson & Johnson): J&J may have disappointed investors when it reported fourth-quarter earnings on Jan. 24.
Any time is a good time to buy solid dividend stocks. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). David Jagielski (Abbott Laboratories): One dividend stock that should be attractive to long-term investors is Abbott Laboratories.
Out of the Dow Jones Industrial Average's 30 components, there are three amazing deals hiding in plain sight.